Hedera Dx Secures €15 Million Series A to bring modern cancer care to patients across the globe

• The €15 million Series A round was led by Vsquared Ventures with participation from another new investor Tesi and existing backers
• Efficient cancer therapies present a massive opportunity for patients globally and Hedera Dx’s solutions are closing a critical gap to access these therapies
• Founded by experienced industry leaders and already deployed across 11 countries, Hedera Dx is working together with a large number of leading cancer centers who have adopted Hedera Dx’s solutions for patients

Lausanne, Switzerland – May 27, 2025 – Hedera Dx, the European techbio company
headquartered in Switzerland, today announced the closing of a €15 million Series A
financing round to drive advanced cancer care. The round was led by Vsquared Ventures,
with Tesi also joining as a new investor alongside significant participation from existing
backers Helsana HealthInvest, Eyrir Venture Management, Inventure and Top Harvest. The
funding will fuel Hedera Dx's mission to overcome structural barriers that prevent cancer
patients from accessing targeted cancer therapies. The founders have led and scaled some
of the most relevant European genetics companies and operations (including Blueprint
Genetics, Roche and Molecular Health) and are now focused on building the next global
leader in healthcare.

Outside the U.S., where centralized testing dominates, healthcare systems require
diagnostics to be performed within hospital labs. Founded in 2021, Hedera Dx has developed
blood-based cancer testing solutions, known as liquid biopsies, to allow for cost efficient and
easy to adopt in-house testing of cancer patients. The solution combines affordability with
unprecedented quality and is already deployed across 11 European countries.

The company is now quickly becoming Europe’s leading platform for precision oncology. In
addition to advanced molecular profiling of cancer patients that provides physicians with
insights for treatment decisions, the AI-native platform also uncovers patient-centric insights
from real-world data to support the development of next generation oncology treatments.

"At Hedera, we are building the infrastructure to make precision cancer care accessible to
every patient and clinician — globally," said Tommi Lehtonen, CEO and co-founder of
Hedera Dx. "While there is a large number of personalized cancer treatments on the market,
a very large part of patients still can't access them. Our solutions empower hospital labs to
perform sophisticated molecular diagnostics locally and cost efficiently."

Dr. Lise Rechsteiner, General Partner at Vsquared Ventures, said: "Hedera Dx is addressing
a critical gap in global oncology care. Hedera's approach tackles the specific challenges of
hospital in-house testing and results in more patients getting tested and more patients having
access to targeted therapies. Hedera Dx’s combination of diagnostics and powerful real-
world data capabilities positions them to become the definitive leader in precision oncology
within healthcare systems outside the US.”

“We’re not only improving access to advanced cancer care for patients — we are creating an
entirely new platform for real-world insights, driving access to life-saving precision oncology
treatments and fueling the next wave of innovative cancer therapies” said Dr. Christian
Meisel, CMO and co-founder of Hedera Dx.

The Series A funding will support continued commercial expansion and further development
of the company's real-world data infrastructure, addressing the vast global oncology market.

Media Contact
Tommi Lehtonen
tlehtonen@hederadx.com
+41 21 588 00 67

About Hedera Dx
Founded in 2021, Hedera Dx is a techbio company dedicated to removing barriers to precision
medicine in oncology. The company's integrated platform combines advanced molecular diagnostics
with comprehensive clinical data to inform treatment decisions and accelerate drug development.
Hedera's team of 20+ professionals brings together expertise in genomics, clinical oncology,
bioinformatics, artificial intelligence, and digital health. For more information, visit www.hederadx.com.

About Vsquared Ventures
Vsquared Ventures backs bold entrepreneurs engineering groundbreaking technologies addressing
some of the world’s most pressing challenges to become global leaders. Investing in deep tech
companies, Vsquared Ventures focuses on new space, energy transition, robotics and manufacturing,
new computing and sensing, AI and next-gen software and tech-bio. Vsquared Ventures has built one
of Europe’s strongest deep tech portfolios, including industry disruptors Isar Aerospace, IQM Quantum
Computing, Zama.ai, cylib, Neura Robotics and The Exploration Company. www.vsquared.vc

About Tesi
Tesi (officially Finnish Industry Investment Ltd) is a state-owned, market-driven investment company
that invests in venture capital and private equity funds and directly in domestic startups and growth
companies, and to new industrial scale businesses.